MIRASOL / GOG-3045
The first ADC to extend life in ovarian cancer, for the roughly one-third of tumours with high folate receptor alpha.
PFS 5.62 vs 3.98 months (HR 0.65) and OS 16.46 vs 12.75 months (HR 0.67; NEJM 2023). Ocular toxicity (blurred vision, keratopathy) is frequent but reversible with eye-drop prophylaxis. Full approval March 2024.
- Median 5.6 vs 4 months with Mirvetuximab compared with Chemotherapy; about 1.6 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 35 percent lower chance of the event at any given time (hazard ratio 0.65, likely range 0.52 to 0.81).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- Median 16.5 vs 12.8 months with Mirvetuximab compared with Chemotherapy; about 3.7 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 33 percent lower chance of the event at any given time (hazard ratio 0.67, likely range 0.5 to 0.89).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Platinum-resistant ovarian cancer with high folate receptor alpha expression, 1-3 prior lines: mirvetuximab soravtansine vs chemotherapy. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (folate receptor); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
453 participants enrolled.
Pages like this
not linked directly; found by shared links- InstitutionStephenson Cancer Center, OU Health
Shares Mirvetuximab soravtansine, Folate receptor alpha, Ovarian cancer, Antibody-drug conjugate (ADC).
- IdeaSequence folate-receptor ADCs by payload class
Shares Mirvetuximab soravtansine, Folate receptor alpha, Ovarian cancer.
- TrialRAINFOL-01 (Rina-S)
Shares Folate receptor alpha, Ovarian cancer, Antibody-drug conjugate (ADC).
- ProductLuveltamab tazevibulin
Shares Folate receptor alpha, Ovarian cancer, Antibody-drug conjugate (ADC).
- TermSulfo-SPDB (disulfide)
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC).
- ProductRinatabart sesutecan
Shares Folate receptor alpha, Ovarian cancer, Antibody-drug conjugate (ADC).
- ProductPafolacianine
Shares Folate receptor alpha, Ovarian cancer.
- CompanySutro Biopharma
Shares Folate receptor alpha, Ovarian cancer, Antibody-drug conjugate (ADC).